Company profile for Myeloid Therapeutics

Myeloid Therapeutics

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

pharmacompass-1-m-2025-12-22

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

Contact Supplier

pharmacompass-2-m-2025-11-03

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

16 News #PharmaBuzz

media
16 News #PharmaBuzz

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer. Our proprietary ATAK™ platform is designed to designed to turn myeloid cells against tumors . These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforci...

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer. Our proprietary ATAK™ platform is designed to designed to turn myeloid cells against tumors . These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforcing the anti-tumor immune response, culminating in cancer eradication.

DCAT WeekDCAT Week

Not Confirmed

Not Confirmed

23-26 March, 2026

New York, U.S.A
BIO Partnering at JPMBIO Partnering at JPM

Not Confirmed

Not Confirmed

12-15 January, 2026

San Francisco Marriott Marquis, California
Biotech ShowcaseBiotech Showcase

Not Confirmed

Not Confirmed

12-14 January, 2026

San Diego, California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

300 Technology Square,Suite 203,Cambridge,Massachusetts 02139

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.myeloidtx.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

CREATE Medicines Introduces Retrot For Rna T-Cell Engineering

30 Oct 2025

// PR NEWSWIRE

Myeloid Rebrands As CREATE Medicines To Advance RNA Immunotherapy

06 Oct 2025

// PR NEWSWIRE

Myeloid Therapeutic to Present at 43rd JP Morgan Health Conference

08 Jan 2025

// PR NEWSWIRE

Myeloid Posters At ASGCT 2024 Annual Meeting

07 May 2024

// PR NEWSWIRE

Prime Medicine and Myeloid Announce Settlement of Pending Disputes

05 Jan 2024

// PR NEWSWIRE

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

06 Dec 2023

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search